Recent Finacing
Recent Raise
Innocrin is a clinical-stage biopharmaceutical developing oral CYP17 lyase–selective small molecules (lead VT-464) for castration-resistant prostate cancer and resistant ER+ and TNBC, advancing MSK/NCI-led Phase 1–2 trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
